Skip to content

Clinical trials

Withdrawn Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma Status: Withdrawn Country / region: United States Clear all

41 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20041
20062
20071
20082
20092
20102
20121
20131
20142
20152
20164
20172
20181
20191
20202
20211
20222
20232
20243

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Withdrawn41

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Masonic Cancer Center, University of Minnesota4
Fred Hutchinson Cancer Center2
Stanford University2
University of Medicine and Dentistry of New Jersey2
Alliance for Clinical Trials in Oncology1
Baptist Health South Florida1
Baylor College of Medicine1
Bellicum Pharmaceuticals1
Case Comprehensive Cancer Center1
Children's Oncology Group1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma41
Leukemia, Myeloid, Acute18
Leukemia13
Leukemia, Lymphocytic, Chronic, B-Cell11
Lymphoma11
Lymphoma, Non-Hodgkin11
Myelodysplastic Syndromes11
Burkitt Lymphoma10
Lymphoma, Large B-Cell, Diffuse10
Lymphoma, B-Cell, Marginal Zone9

Trials

Showing 1 to 25 of 41. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.